Comorbidity of Chronic Obstructive Pulmonary Disease and Cardiovascular Diseases: Place of Therapy with Modern β-Adrenoblockers
https://doi.org/10.18087/cardio.2019.6.n458
Abstract
Chronic obstructive pulmonary disease (COPD) is the fourth largest cause of worldwide mortality. Presence of comorbidities is registered in 96% of COPD patients. The most important of these are cardiovascular diseases (coronary artery disease, arterial hypertension, chronic heart failure), which contribute to COPD patients’ mortality in every third case. COPD and cardiovascular diseases have common risk factors and pathogenesis mechanisms. Cardioselective beta-blockers reduce morbidity risk and frequency of COPD exacerbation, are effective and safe in treatment of COPD patients.
Keywords
Supporting agencies: I.M. Sechenov’s First Moscow State Medical University of Ministry of Health (Sechenov University). No conflict of interest.
About the Authors
Yu. N. Belenkov
I.M. Sechenov’s First Moscow State Medical University of Ministry of Health (Sechenov University)
Russian Federation
Yuri Nikitich Belenkov – Academician of Russian Science Academy, professor, MD, PhD, Chair of Hospital Department №1 of Medical Faculty
Russian Federation
Yuri Nikitich Belenkov – Academician of Russian Science Academy, professor, MD, PhD, Chair of Hospital Department №1 of Medical Faculty
O. A. Tsvetkova
I.M. Sechenov’s First Moscow State Medical University of Ministry of Health (Sechenov University)
Russian Federation
Olga Alexandrovna Tsvetkova – professor, MD, PhD, Hospital Department №1 of Medical Faculty
Russian Federation
Olga Alexandrovna Tsvetkova – professor, MD, PhD, Hospital Department №1 of Medical Faculty
E. V. Privalova
I.M. Sechenov’s First Moscow State Medical University of Ministry of Health (Sechenov University)
Russian Federation
Elena Vitalievna Privalova – professor, MD, PhD, Hospital Department №1 of Medical Faculty
Russian Federation
Elena Vitalievna Privalova – professor, MD, PhD, Hospital Department №1 of Medical Faculty
G. V. An
I.M. Sechenov’s First Moscow State Medical University of Ministry of Health (Sechenov University)
Russian Federation
Galina Viktorovna An – assistant professor, MD, PhD, Hospital Department №1 of Medical Faculty
Russian Federation
Galina Viktorovna An – assistant professor, MD, PhD, Hospital Department №1 of Medical Faculty
I. S. Ilgisonis
I.M. Sechenov’s First Moscow State Medical University of Ministry of Health (Sechenov University)
Russian Federation
Irina Sergeevna Ilgisonis – associate professor, MD, PhD, Hospital Department №1 of Medical Faculty
Russian Federation
Irina Sergeevna Ilgisonis – associate professor, MD, PhD, Hospital Department №1 of Medical Faculty
O. O. Voronkova
I.M. Sechenov’s First Moscow State Medical University of Ministry of Health (Sechenov University)
Russian Federation
Olga Olegovna Voronkova – assistant professor, MD, PhD, Hospital Department №1 of Medical Faculty
Russian Federation
Olga Olegovna Voronkova – assistant professor, MD, PhD, Hospital Department №1 of Medical Faculty
References
1. Barabanova E. N. GOLD 2017: What change were made in global strategy of treatment of chronic obstructive pulmonary disease and why? Russian Pulmonology. 2017;27(2):274–82. [Russian]. DOI: 10.18093/0869-0189-2017-27-2-274-282
2. Aisanov Z, Avdeev S, Arkhipov V, Belevskiy A, Chuchalin A, Leshchenko I et al. Russian guidelines for the management of COPD: algorithm of pharmacologic treatment. International Journal of Chronic Obstructive Pulmonary Disease. 2018;13:183– 7. DOI: 10.2147/COPD.S153770
3. Mathers CD, Loncar D. Projections of Global Mortality and Burden of Disease from 2002 to 2030. PLoS Medicine. 2006;3(11):e442. DOI: 10.1371/journal.pmed.0030442
4. Lamprecht B, McBurnie MA, Vollmer WM, Gudmundsson G, Welte T, Nizankowska-Mogilnicka E et al. COPD in Never Smokers: results from the population-based burden of obstructive lung disease study. Chest. 2011;139(4):752–63. DOI: 10.1378/chest.10-1253
5. Chuchalin A, Khaltaev N, Antonov N, Galkin D, Manakov L, Antonini P et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. International Journal of Chronic Obstructive Pulmonary Disease. 2014;12:963–74. DOI: 10.2147/COPD.S67283
6. Grigor’eva N. Y., Mayorova M. V., Kuznetsov A. N. Application of Long-Acting β2-Agonists in the Therapy of Chronic Obstructive Pulmonary Disease in Patients with Сonсomitant Ischemic Heart Disease. Modern Technologies in Medicine. 2017;9(1):156–61. [Russian]. DOI: 10.17691/stm2017.9.1.20
7. Jabbour A, Macdonald PS, Keogh AM, Kotlyar E, Mellemkjaer S, Coleman CF et al. Differences Between Beta-Blockers in Patients With Chronic Heart Failure and Chronic Obstructive Pulmonary Disease. Journal of the American College of Cardiology. 2010;55(17):1780–7. DOI: 10.1016/j.jacc.2010.01.024
8. Bhatt SP, Dransfield MT. Chronicobstructivepulmonarydiseaseand cardiovascular disease. Translational Research. 2013;162(4):237– 51. DOI: 10.1016/j.trsl.2013.05.001
9. Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V et al. Comorbidities and Risk of Mortality in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 2012;186(2):155–61. DOI: 10.1164/ rccm.201201-0034OC
10. Curkendall SM, deLuise C, Jones JK, Lanes S, Stang MR, Goehring E et al. Cardiovascular Disease in Patients with Chronic Obstructive Pulmonary Disease, Saskatchewan Canada. Annals of Epidemiology. 2006;16(1):63–70. DOI: 10.1016/j.annepidem.2005.04.008
11. Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. International Journal of Chronic Obstructive Pulmonary Disease. 2009;4:337–49. PMID: 19802349
12. McAllister DA, Maclay JD, Mills NL, Leitch A, Reid P, Carruthers R et al. Diagnosis of myocardial infarction following hospitalisa- tion for exacerbation of COPD. European Respiratory Journal. 2012;39(5):1097–103. DOI: 10.1183/09031936.00124811
13. Brekke PH, Omland T, Smith P, Søyseth V. Underdiagnosis of myocardial infarction in COPD – Cardiac Infarction Injury Score (CIIS) in patients hospitalised for COPD exacerbation. Respiratory Medicine. 2008;102(9):1243–7. DOI: 10.1016/j. rmed.2008.04.010
14. Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased Risk of Myocardial Infarction and Stroke Following Exacerbation of COPD. Chest. 2010;137(5):1091–7. DOI: 10.1378/chest.09-2029
15. Karoli N. A., Borodkin A. V., Rebrov A. P. Diagnostics of chronic cardiac insufficiency in patients with chronic obstructive pulmonary disease. Clinical Medicine. 2015;93(5):50–6. [Russian]
16. Maiorova М. V., Grigor’eva N. Yu., Kuznetsov A. N. Features of management of patients with chronic obstructive pulmonary disease having various rhythm disturbances. Medical Almanac. 2018;1:101–5. [Russian]. DOI: 10.21145/2499-9954-2018-1-101-105
17. Lee V. V., Timofeeva N. Yu., Zadionchenko V. S., Adasheva T. V., Vysotskaya N. V. Recent aspects of cardiac remodeling in patients with chronic obstructive pulmonary disease. Rational Pharmacotherapy in Cardiology. 2018;14(3):379–86. [Russian]. DOI: 10.20996/1819-6446-2018-14-3-379-386
18. Leonova E. I., Shechyan G. G., Zadionchenko V. S., Adasheva T. V., Deev A. D., Fedorova I. V. Cardiopulmonary factors associated with atrial fibrillation in patients with chronic obstructive pulmonary disease. Rational Pharmacotherapy in Cardiology. 2016;12(1):26–30. [Russian]. DOI: 10.20996/1819-6446-2016-12-1-26-30
19. Grigor’eva N. Yu., Kapustina M. V., Kuznetsov A. N., Koroleva T. V. Treatment of chronic obstructive pulmonary disease with concomitant cardiovascular disease. The Doctor. 2016;7:70–3. [Russian]
20. Thomsen M, Dahl M, Lange P, Vestbo J, Nordestgaard BG. Inflammatory Biomarkers and Comorbidities in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 2012;186(10):982–8. DOI: 10.1164/rccm.201206-1113OC
21. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L et al. The Nature of Small-Airway Obstruction in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine. 2004;350(26):2645–53. DOI: 10.1056/NEJMoa032158
22. Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Therapeutic Advances in Respiratory Disease. 2018;12:175346581775052. DOI: 10.1177/1753465817750524
23. Provotorov V. M., Budnevskiy A. V., Shishkina E. S. Dynamics of Quality of Life in Patients with Chronic Obstructive Pulmonary Disease in the Acute Stage and Related Ischemic Heart Disease When Using Roflumilast. Science Prospects. 2017;3(90):38–42. [Russian]
24. Weir-McCall JR, Liu-Shiu-Cheong PS, Struthers AD, Lipworth BJ, Houston JG. Disconnection of pulmonary and systemic arterial stiffness in COPD. International Journal of Chronic Obstructive Pulmonary Disease. 2018;13:1755–65. DOI: 10.2147/COPD.S160077
25. Chuchalin A. G., Tseimakh I. Ya., Momot A. P., Mamaev A. N., Karbyshev I. A., Strozenko L. A. Thrombogenic risk factors in patients with exacerbation of chronic obstructive pulmonary disease. Clinical Medicine. 2015;93(12):18–23. [Russian]
26. Miravitlles M, Vogelmeier C, Roche N, Halpin D, Cardoso J, Chuchalin AG et al. A review of national guidelines for management of COPD in Europe. European Respiratory Journal. 2016;47(2):625–37. DOI: 10.1183/13993003.01170-2015
27. Jones DA, Timmis A, Wragg A. Novel drugs for treating angina. BMJ. 2013;347:f4726–f4726. DOI: 10.1136/bmj.f4726
28. Wang W-H, Cheng C-C, Mar G-Y, Wei K-C, Huang W-C, Liu C-P. Improving outcomes in chronic obstructive pulmonary disease by taking beta-blockers after acute myocardial infarction: a nationwide observational study. Heart and Vessels. 2019; [Epub ahead of print]. DOI: 10.1007/s00380-019-01341-0
29. Rasmussen DB, Bodtger U, Lamberts M, Nicolaisen SK, Sessa M, Capuano Aet al. Beta-blocker, aspirin, andstatinusageafterfirst-time myocardial infarction in patients with chronic obstructive pulmonary disease: a nationwide analysis from 1995 to 2015 in Denmark. European Heart Journal - Quality of Care and Clinical Outcomes. 2019; [Epub ahead of print]. DOI: 10.1093/ehjqcco/qcy063
30. Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons? European Respiratory Review. 2018;27(149):180057. DOI: 10.1183/16000617.0057-2018
31. Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Mohacsi P et al. Effect of Carvedilol on Survival in Severe Chronic Heart Failure. New England Journal of Medicine. 2001;344(22):1651–8. DOI: 10.1056/NEJM200105313442201
32. Taniguchi A, Miyahara N, Oda N, Morichika D, Ichihara E, Oze I et al. Protective Effects of Bisoprolol against Acute Exacerbation in Moderate-to-Severe Chronic Obstructive Pulmonary Disease. Acta Medica Okayama. 2017;71(5):453–7. DOI: 10.18926/AMO/55446
33. Zeng L, Hu, Liu J, Zhang H-Y, Cui H. Impact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease. Clinical Interventions in Aging. 2013;8:1157. DOI: 10.2147/CIA.S49644
34. Oshchepkova E. V., Lazareva N. V., Chazova I. E. Features of the clinics and treatment of patients with obesity and hyperten- sion (according to the National register of arterial hypertension). Therapeutic Archive. 2018;90(9):8–14. [Russian]. DOI: 10.26442/terarkh20189098-14
35. D’Urzo A, Vogelmeier C. Future of chronic obstructive pulmonary disease management. Expert Review of Respiratory Medicine. 2012;6(3):285–99. DOI: 10.1586/ers.12.20
36. Zafiraki V. K., Skaletskiy K. V., Namitokov A. M., Kosmacheva E. D., Shulzhenko L. V., Omarov A. A. et al. Chronic Obstructive Pulmonary Disease as a Factor of Unfavorable Cardiovascular Prognosis After Percutaneous Coronary Interventions in Ischemic Heart Disease. Kardiologiia. 2015;55(10):41–5. [Russian] PMID: 28294793]
37. Petta V, Perlikos F, Loukides S, Bakakos P, Chalkias A, Iacovidou N et al. Therapeutic effects of the combination of inhaled beta2-agonists and beta-blockers in COPD patients with cardiovascular disease. Heart Failure Reviews. 2017;22(6):753–63. DOI: 10.1007/s10741-017-9646-z
38. Statsenko M. E., Derevyanchenko M. V. Th Place of β-adrenoblockers in the Treatment of Cardiovascular Disease in Patients With Chronic Obstructive Pulmonary Disease. Kardiologiia. 2012;52(12):57–63. [Russian]
39. Martiniuc C, Branishte T. The use of beta blocker Nebivolol in patients with chronic obstructive pulmonary disease in association with arterial hypertension. Revista Medico-Chirurgicala a Societatii De Medici Si Naturalisti Din Iasi. 2012;116(1):218–21. PMID: 23077899
40. Albouaini K, Andron M, Alahmar A, Egred M. Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions. International Journal of Chronic Obstructive Pulmonary Disease. 2007;2(4):535–40. PMID: 18268926
41. Ni Y, Shi G, Wan H. Use of Cardioselective β-Blockers in Patients with Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomized, Placebo-controlled, Blinded Trials. Journal of International Medical Research. 2012;40(6):2051–65. DOI: 10.1177/030006051204000602
42. Egred M, Shaw S, Mohammad B, Waitt P, Rodrigues E. Under- use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. QJM: An International Journal of Medicine. 2005;98(7):493–7. DOI: 10.1093/qjmed/hci080
43. Gurova A. Yu., Chaplygin A. V., Svet A. V., Morozova T. E., Tsvetkova O. A. Features of rational pharmacotherapy with beta-blockers in combination of coronary heart disease and chronic obstructive pulmonary disease. Attending physician. 2012;2:15. [Russian]
44. Peters JI, Gomez-Dinger PL, Freeman GL, Galbreath AD, Smith PB. Use of Beta Blockers in Congestive Heart Failure(CHF) Patients with COPD and/or Asthma. Chest. 2004;126(4):921S. DOI: 10.1378/chest.126.4_MeetingAbstracts.921S
45. Tsvetkova O. A., Veselovskaya M. V. Efficacy of a cardioselec-tive betal-adrenoblocker bisoprolol in patients with chronic obstructive pulmonary disease in combination with ischemic heart disease. Therapeutic Archive. 2007;79(3):25–9. [Russian]
46. Geltser B. I., Kurpatov I. G., Kotelnikov V. N., Zayats Yu. V. Chronic obstructive pulmonary disease and cerebrovascular diseases: functional and clinical aspect of comorbidity. Therapeutic Archive. 2018;90(3):81–8. [Russian]. DOI: 10.26442/terarkh201890381-88
47. Du Q, Sun Y, Ding N, Lu L, Chen Y. Beta-Blockers Reduced the Risk of Mortality and Exacerbation in Patients with COPD: A Meta-Analysis of Observational Studies. PLoS ONE. 2014;9(11):e113048. DOI: 10.1371/journal.pone.0113048
48. Staszewsky L, Wong M, Masson S, Barlera S, Carretta E, Maggioni AP et al. Clinical, Neurohormonal, and Inflammatory Markers and Overall Prognostic Role of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure: Data From the Val-HeFT Heart Failure Trial. Journal of Cardiac Failure. 2007;13(10):797–804. DOI: 10.1016/j.cardfail.2007.07.012
49. Callaerts-Vegh Z, Evans KLJ, Dudekula N, Cuba D, Knoll BJ, Callaerts PFK et al. Effects of acute and chronic administration of -adrenoceptor ligands on airway function in a murine model of asthma. Proceedings of the National Academy of Sciences. 2004;101(14):4948–53. DOI: 10.1073/pnas.0400452101
50. Nguyen LP, Omoluabi O, Parra S, Frieske JM, Clement C, Ammar- Aouchiche Z et al. Chronic Exposure to Beta-Blockers Attenuates Inflammation and Mucin Content in a Murine Asthma Model. American Journal of Respiratory Cell and Molecular Biology. 2008;38(3):256–62. DOI: 10.1165/rcmb.2007-0279RC
Review
For citations:
Belenkov Yu.N., Tsvetkova O.A., Privalova E.V., An G.V., Ilgisonis I.S., Voronkova O.O. Comorbidity of Chronic Obstructive Pulmonary Disease and Cardiovascular Diseases: Place of Therapy with Modern β-Adrenoblockers. Kardiologiia. 2019;59(6):48-55. (In Russ.) https://doi.org/10.18087/cardio.2019.6.n458
Views:
2413
Email this article 
Post a Comment 
